Glucose as a prognostic factor in ovarian carcinoma
- PMID: 19156916
- PMCID: PMC2649990
- DOI: 10.1002/cncr.24126
Glucose as a prognostic factor in ovarian carcinoma
Abstract
Background: Research suggests that glucose levels in cancer patients may be an important prognostic indicator. In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time in ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease-specific survival time and time to recurrence in ovarian cancer patients.
Methods: Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease-free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate.
Results: Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2.01; P = .02) and DFI (HR, 2.48; P = .001) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set.
Conclusions: These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma.
(c) 2009 American Cancer Society.
Figures
Comment in
-
Sugar fuels cancer.Cancer. 2009 Mar 1;115(5):918-21. doi: 10.1002/cncr.24125. Cancer. 2009. PMID: 19156846 No abstract available.
References
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2007;58:71–96. - PubMed
-
- Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther. 2005;4:217–224. - PubMed
-
- Markmann S, Gerber B, Briese V. Prognostic value of Ca 125 levels during primary therapy. Anticancer Res. 2007;27:1837–1840. - PubMed
-
- Park SM, Lim MK, Shin SA, et al. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National health insurance corporation study. J Clin Oncol. 2006;24:5017–5024. - PubMed
-
- Ali NA, O’Brien JM, Blum W, et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer. 2007;110:96–102. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R21CA88293/CA/NCI NIH HHS/United States
- P30 CA086862/CA/NCI NIH HHS/United States
- R01-CA100045/CA/NCI NIH HHS/United States
- R01 CA110793/CA/NCI NIH HHS/United States
- CA110793/CA/NCI NIH HHS/United States
- K07-CA 093512/CA/NCI NIH HHS/United States
- R01 CA100045/CA/NCI NIH HHS/United States
- R21 CA088293/CA/NCI NIH HHS/United States
- R01-CA104825/CA/NCI NIH HHS/United States
- CA199298/CA/NCI NIH HHS/United States
- R01 CA104825/CA/NCI NIH HHS/United States
- K07 CA093512/CA/NCI NIH HHS/United States
- P50 CA083639/CA/NCI NIH HHS/United States
- CF2002-0000832/PHS HHS/United States
- P30-CA086862/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
